A new trading day began on Tuesday, with TG Therapeutics Inc (NASDAQ: TGTX) stock price down -4.62% from the previous day of trading, before settling in for the closing price of $37.25. TGTX’s price has ranged from $12.93 to $43.32 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 2514.62%. Meanwhile, its annual earnings per share averaged 545.38%. With a float of $141.43 million, this company’s outstanding shares have now reached $155.84 million.
Considering the fact that the conglomerate employs 338 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 88.26%, operating margin of 12.74%, and the pretax margin is 7.78%.
TG Therapeutics Inc (TGTX) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of TG Therapeutics Inc is 9.96%, while institutional ownership is 62.26%. The most recent insider transaction that took place on Jan 03 ’25, was worth 343,443. In this transaction CFO of this company sold 11,337 shares at a rate of $30.29, taking the stock ownership to the 670,632 shares. Before that another transaction happened on Jan 06 ’25, when Company’s CFO sold 10,021 for $28.53, making the entire transaction worth $285,939. This insider now owns 660,611 shares in total.
TG Therapeutics Inc (TGTX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.34 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 545.38% per share during the next fiscal year.
TG Therapeutics Inc (NASDAQ: TGTX) Trading Performance Indicators
Here are TG Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 5.03. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 16.96.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.14, a number that is poised to hit 0.16 in the next quarter and is forecasted to reach 1.93 in one year’s time.
Technical Analysis of TG Therapeutics Inc (TGTX)
Compared to the last year’s volume of 2.71 million, its volume of 3.45 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 24.96%. Additionally, its Average True Range was 2.63.
During the past 100 days, TG Therapeutics Inc’s (TGTX) raw stochastic average was set at 51.55%, which indicates a significant increase from 19.02% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 44.23% in the past 14 days, which was lower than the 65.28% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $35.47, while its 200-day Moving Average is $27.95. Nevertheless, the first resistance level for the watch stands at $37.98 in the near term. At $40.42, the stock is likely to face the second major resistance level. The third major resistance level sits at $41.98. If the price goes on to break the first support level at $33.98, it is likely to go to the next support level at $32.42. Now, if the price goes above the second support level, the third support stands at $29.98.
TG Therapeutics Inc (NASDAQ: TGTX) Key Stats
With a market capitalization of 5.58 billion, the company has a total of 157,071K Shares Outstanding. Currently, annual sales are 329,000 K while annual income is 23,380 K. The company’s previous quarter sales were 108,190 K while its latest quarter income was 23,330 K.
